Go Deep
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,515 | 39.8 | 5.30 | 0.47 | 445.00 |
| Oct 2026 | 20,893 | 39.3 | 5.26 | 0.47 | 441.40 |
SMS Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,069,649,000.0 | 2,379,475,000.0 | 2,104,470,000.0 | 2,424,295,000.0 |
| Net Profit | 209,090,000.0 | 327,139,000.0 | 234,720,000.0 | 253,127,000.0 |
| EPS | 2.2 | 3.6 | 2.6 | 2.8 |
SMS Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 8,832,318,000.0 | 7,792,740,000.0 | 7,064,565,000.0 | 5,197,468,000.0 | — |
| Net Profit | 1,019,891,000.0 | 691,356,000.0 | 498,260,000.0 | -70,593,000.0 | — |
| EPS | 11.2 | 8.2 | 5.9 | -0.8 | — |
SMS Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 13,624,392,000.0 | 11,526,813,000.0 | 10,340,926,000.0 | 8,796,101,000.0 | — |
| Total Liabilities | 5,766,303,000.0 | 5,130,369,000.0 | 4,977,637,000.0 | 4,190,849,000.0 | — |
| Total Equity | 7,858,088,000.0 | 6,396,443,000.0 | 5,363,289,000.0 | 4,605,252,000.0 | — |
Owes vs Owns
SMS Pharmaceuticals Limited owed ₹0.42 for every ₹1 it owned in Mar 2026, down from ₹0.48 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.42× | 0.45× | 0.48× | 0.48× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
SMS Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 3.4%Receivables 15.8%Inventory 25.8%Fixed assets (tangible) 50.2%Long-term investments 1.9%Other assets 2.7%
How it's funded — Mar 2026
Short-term debt 14.2%Long-term debt 12.6%Payables 8.8%Other liabilities 6.7%Shareholders' equity 57.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 46.0 | 41.5 | 36.1 | 7.4 |
| Receivables | 215.9 | 203.2 | 236.2 | 148.3 |
| Inventory | 351.2 | 284.7 | 233.7 | 223.5 |
| Fixed assets (tangible) | 684.2 | 574.5 | 478.7 | 449.4 |
| Intangible assets | 2.8 | 2.1 | 2.7 | 1.5 |
| Long-term investments | 26.3 | 11.7 | 10.9 | 10.5 |
| Other assets | 36.2 | 34.9 | 35.7 | 39.0 |
| Liabilities & equity | ||||
| Short-term debt | 193.4 | 171.4 | 158.1 | 131.4 |
| Long-term debt | 171.6 | 139.4 | 122.1 | 121.1 |
| Payables | 120.4 | 113.9 | 151.3 | 107.4 |
| Other liabilities | 91.1 | 88.4 | 66.3 | 59.1 |
| Shareholders' equity | 785.8 | 639.6 | 536.3 | 460.5 |
| Net tangible assets | 783.0 | 637.5 | 533.7 | 459.1 |
SMS Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 592,236,000.0 | 817,093,000.0 | 501,247,000.0 | 224,500,000.0 | — |
| Investing Activities | -1,307,802,000.0 | -1,234,289,000.0 | -520,720,000.0 | -297,561,000.0 | — |
| Financing Activities | 760,345,000.0 | 470,792,000.0 | 306,790,000.0 | -319,689,000.0 | — |